Overview

A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (what the body does to the medication) and relative bioavailability of 3 newly developed abiraterone acetate tablet formulations compared with the current commercial abiraterone acetate tablet formulation in healthy male participants, under fasted conditions, at a single dose of 1000 mg.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Treatments:
Abiraterone Acetate